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It is generally believed that increase in adult contractile cardiac mass
can be accomplished only by hypertrophy of existing myocytes.
Documentation of myocardial regeneration in acute stress has chal-
lenged this dogma and led to the proposition that myocyte renewal
is fundamental to cardiac homeostasis. Here we report that in human
aortic stenosis, increased cardiac mass results from a combination of
myocyte hypertrophy and hyperplasia. Intense new myocyte forma-
tion results from the differentiation of stem-like cells committed to
the myocyte lineage. These cells express stem cell markers and
telomerase. Their number increased >13-fold in aortic stenosis. The
finding of cell clusters with stem cells making the transition to
cardiogenic and myocyte precursors, as well as very primitive myo-
cytes that turn into terminally differentiated myocytes, provides a link
between cardiac stem cells and myocyte differentiation. Growth and
differentiation of these primitive cells was markedly enhanced in
hypertrophy, consistent with activation of a restricted number of
stem cells that, through symmetrical cell division, generate asynchro-
nously differentiating progeny. These clusters strongly support the
existence of cardiac stem cells that amplify and commit to the
myocyte lineage in response to increased workload. Their presence is
consistent with the notion that myocyte hyperplasia significantly
contributes to cardiac hypertrophy and accounts for the subpopula-
tion of cycling myocytes.
Myocyte turnover occurs in the human heart, and myocytereplication is markedly enhanced in acute pathologic states
(1, 2). However, new myocyte generation is attenuated with pro-
longed ventricular decompensation and end-stage cardiac failure
(1, 3). Although myocyte proliferation has been interpreted as the
ultimate reserve of the stressed myocardium (4), these observations
indicate an opposite phenomenon: myocyte multiplication is higher
acutely than chronically. The decrease in myocyte replication with
time suggests that these cells undergo a limited number of dou-
blings, perhaps behaving as amplifying cells that concurrently divide
and differentiate until they reach growth arrest and the adult
phenotype (5). The recognition that myocytes and vascular struc-
tures can be formed from primitive cells resident in or homed to the
myocardium from the circulation (6, 7) is consistent with this
possibility and identifies a plausible origin of these cycling myocytes
(8). This outlook has raised the question as to whether the regen-
erative capacity of the myocardium in acute overload also partici-
pates in the hypertrophic response to chronic stimuli with modest
ventricular dysfunction, such as in patients with aortic stenosis (9).
Because the majority of myocytes in the adult heart are termi-
nally differentiated and do not reenter the cell cycle, replicating
myocytes originate either from the activation of primitive stem or
progenitor cardiac cells or by the residual growth of a subgroup of
nonterminally differentiated myocytes. In the first case, undiffer-
entiated and early committed cells should be present in the heart.
These cells would be expected to express stem cell markers (5, 7)
and telomerase (10, 11), divide rapidly upon stimulation (11, 12),
and give rise to myocytes at various stages of maturation. In the
second case, myocyte regeneration should be self-limiting and
restricted to the acute phase.
The results presented here document that human aortic stenosis
promotes intense myocyte formation through the differentiation of
cardiac stem cells committed to the myocyte lineage. Thus, the
increased cardiac mass results from a combination of myocyte
hypertrophy and hyperplasia.
Materials and Methods
Patients. Patients with aortic stenosis (n  36) had valve replace-
ment for rheumatic disease or degenerative calcification. Hyper-
tension was present in 21 cases and coronary disease in 7. Treat-
ment included angiotensin-converting enzyme (ACE) inhibitors,
calcium blockers, and diuretics. Heart size and function were
measured by echocardiography and catheterization (13). Specimens
were obtained by myectomy of the outflow tract and fixed in
formalin (n  36). Twelve biopsies were frozen (n  12). Control
hearts were collected, within 24 h after death, from patients, 71 
8 years old, with no cardiac diseases (n 12; 7 males and 5 females).
Samples of three normal hearts were frozen for biochemistry (14).
Cell Markers and Mitotic Index. Several Abs were used alone or in
combination to identify putative cardiac stem cells and committed
progenies. Colabeling with stem cell antigens and markers of cell
differentiation was required to establish whether maturing cells
originated from primitive cells. Distinct markers of cell differenti-
ation were also used because they appear at various stages of cell
development.
Stem cell markers included mAb against c-kit (DAKO), the
receptor of stem cell factor, MDR1 (Chemicon), a protein extrud-
ing toxic substances and Hoechst dye, and Sca-1-reactive protein
(Cedarlane, Hornby, ON, Canada), which is involved in self-
renewal of hemopoietic stem cells. Myocyte markers were as
follows: cardiac myosin, -sarcomeric actin, desmin, connexin-43,
N-cadherin, GATA-4, GATA-5, MEF2, and nestin. Smooth muscle
cells markers: -smooth-muscle-actin and transforming growth
factor 1 receptor. Fibroblast marker: vimentin. Endothelial mark-
ers: von Willebrand factor, Flk1, and CD31. Skeletal muscle nuclear
proteins (MyoD, myogenin, and Myf5), neural proteins (microtu-
bule-associated protein 1b, neurofilament 200 and glial fibrillar
acidic protein), and hemopoietic cell markers (glycophorin-A,
CD45, CD45RO, and CD8) were examined. For each staining,
50–100 and 600–1,200 mm2 of tissue was sampled from hypertro-
phied and control heart, respectively (1, 2, 7). Cdc6, MCM5, Ki67,
and cyclin B1 Ab labeled cycling cells; 500–9,000 and 5,000–27,000
myocyte nuclei were counted in each hypertrophied and control
heart. Corresponding sampling for mitotic indices was 4,000–14,000
and 50,000–170,000 nuclei. In each heart, myocyte diameter was
measured across the nucleus in 100–200 cells cut transversely and
the cross-sectional area was computed (4).
Western Blotting. Protein lysates were precipitated with a Sca-1
mouse mAb (PharMingen). After PAGE, proteins were transferred
and exposed to the same mAb (11). A Sca-1 epitope was seen at
18.4 kDa.
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Telomeric Repeat Amplification Protocol. Samples were homoge-
nized in 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesul-
fonate buffer and were centrifuged. Untreated and RNase-treated
extracts, 0.5 and 1g, were incubated with [-32P]ATP-end-labeled
telomerase substrate (5-AATCCGTCGAGCAGAGTT-3), Taq
DNA polymerase, and anchored reverse primer [5-GCGCGC-
(CTTACC)3CTAACC-3]. PCR products were separated by
PAGE. Telomerase reaction generated a 6-bp ladder (11).
Telomeric Restriction Fragment (TRF) Analysis. Electrophoresed
genomic DNA, digested with RsaI and HinfI and transferred to a
nylon membrane, was hybridized with 32P-end-labeled (C3TA2)3
probe. TRF length was determined by densitometry (11, 15).
Statistics. Results are means  SD, and P  0.05 was determined
by Student’s t test.
Results
Patients. Table 1, which is published as supporting information of
the PNAS web site, www.pnas.org, lists echocardiographic (n 36)
and hemodynamic (n  20) data, and the duration of the disease
from echocardiographic diagnosis to surgery (3  5 years). Ven-
tricular pressures and aortic gradient were increased. Ejection
fraction and fractional shortening were not altered.
Putative Primitive Cells, Progenitors, and Precursors. Primitive cells
positive for c-kit, MDR1, or Sca-1-reactive protein only, i.e.,
putative cardiac stem cells, were 6 2m in diameter (Fig. 1 A–C).
These cells were negative for antigens of hemopoietic lineages (Fig.
7, which is published as supporting information on the PNAS web
site), transcription factors of cardiac and skeletal muscle cells (Fig.
8, which is published as supporting information on the PNAS web
site), and cytoplasmic markers of myocytes, fibroblasts, and endo-
thelial, smooth muscle, and neural cells (Figs. 9 and 10, which are
published as supporting information on the PNAS web site). A
Sca-1-like epitope was confirmed biochemically in myocardial
samples. Sca-1 Ab-reactive protein increased with aortic stenosis
(Fig. 11A, which is published as supporting information on the
PNAS web site). Cells positive for this protein alone or with c-kit
were also found in human bone marrow (Fig. 11B).
Extrapolating from cardiac ontogeny (16, 17), the presence of
stem cell antigens and the exclusive expression of the cardiac
transcription factor GATA-4 (16) or GATA-4 and the myocyte
transcription factor MEF2 (17) identified putative cardiac and
myocyte progenitors, respectively. Putative myocyte precursors
differed from progenitors by the expression of cytoplasmic proteins,
such as cardiac myosin (Fig. 2). The presence of stem cell antigens,
GATA-4, MEF2, and myosin, established a sequential lineage
commitment of primitive cells into cardiac progenitors, myocyte
progenitors, and myocyte precursors. Surface antigens were no
longer detectable in myosin-positive cells, i.e., amplifying myocytes,
that were larger than myocyte precursors but much smaller than
adult myocytes (Fig. 12 A and B, which is published as supporting
information on the PNAS web site). With respect to controls (n 
12), aortic stenosis (n  36) led to an 8- to 19-fold increase in the
number of lineage negative c-kit, lineage negative MDR1, or
lineage negative Sca-1-like positive cells and to a 10- to 26-fold
increase in cardiac progenitors and myocyte progenitors and pre-
cursors (Fig. 12C).
Cycling Primitive and Early Committed Cells. Two markers of cell
proliferation were used to determine the dynamic state of primitive
and committed cells (Fig. 13 A–E, which is published as supporting
information on the PNAS web site). Ki67 is a nuclear protein
expressed in late G1, S, G2, prophase and metaphase, decreasing in
anaphase and telophase (18). MCM5 is expressed throughout G1
and S, becomes undetectable in G2 and early mitosis, and is present
again in anaphase and telophase (19, 20). With respect to controls
(n  12), aortic stenosis (n  36) led to a 70- to 140-fold increase
in Ki67-labeled c-kit, MDR1, and Sca-1-like primitive cells. Ki67-
positive cardiac progenitors and myocyte progenitors–precursors
combined increased 65- to 240-fold. The analysis of MCM5 was
restricted to primitive cells (controls, n 8; patients, n 16), which
markedly increased with aortic stenosis (Fig. 13F). The values were
higher than Ki67, and this difference, most likely, reflected a larger
fraction of cycling cells in G1.
Telomerase and Cycling Cells. Telomerase is expressed in stem cells
of self-renewing organs, such as bone marrow, skin, brain, and
intestine (12, 21). Telomerase is a reverse transcriptase that during
the cell cycle synthesizes telomeric repeats at the end of chromo-
somes, preventing loss of DNA (10, 11, 21). Telomerase is present
in dividing cells and is absent from resting and terminally differ-
entiated cells (10). Telomerase and MCM5 were detected in cycling
cells expressing stem cell antigens alone or transcription factors and
cardiac myosin (Fig. 3 A–D). In comparison with controls (n  8),
aortic stenosis (n  16) resulted in a 90- to 120-fold increase in all
cell categories positive for telomerase and MCM5 (Fig. 3E; P 
0.001). Together with primitive cells, telomerase and MCM5 were
detected in myocytes (Fig. 14, which is published as supporting
information on the PNAS web site) that did not express stem cell
antigens and had a 131  15 m2 cross-sectional area. These
amplifying myocytes increased 190-fold with aortic stenosis (Fig.
3E; P  0.001).
On this basis, telomerase activity was measured. The optical
density of the 6-bp ladder reflected the number of telomerase
substrate oligonucleotides extended by telomerase (Fig. 3F). Aortic
stenosis increased enzyme activity from a 25  3 (n  3) control
value to 88  29 (n  12; P  0.001). However, telomeric length
decreased (Fig. 3G: controls 9 1 kbp, n 3; patients 3.3
Fig. 1. Putative cardiac stem cells. Shown are detection of c-kit (A, green), MDR1 (B, purple), and Sca-1-reactive protein (C, yellow) in primitive cells (arrows)
of hypertrophied hearts. Nuclei are stained by propidium iodide (PI; blue) and myocytes by cardiac myosin (red). (Bars  10 m.)











0.5 kbp, n  6; P  0.001), indicating that telomerase activity did
not prevent telomeric shortening.
Cell Clusters. Myocyte commitment of putative cardiac stem cells
and their amplification and differentiation predicted that clus-
ters of primitive cells, progenitors, precursors and small devel-
oping myocytes had to be present in the hypertrophied myocar-
dium. This organization would reflect intense expansion and
maturation of stem or progenitor cells. Clusters of undifferen-
tiated and early differentiating cells positive for stem cell anti-
gens were a consistent finding of aortic stenosis (Fig. 4 A–C).
Aggregates of small mostly cycling and telomerase competent
myocyte precursors and amplifying myocytes were common (Fig.
4 B–I). The majority of these clusters contained 6–12 cells at
different stages of differentiation and myocyte commitment
(Fig. 4 A–C). This arrangement was strongly suggestive of clonal
Fig. 2. Commitment of primitive cells with cardiac hypertrophy. (A and B; the same field) A cardiac progenitor (A, arrowhead) shows c-kit on the surface membrane
(green) and GATA-4 (A, red) in the nucleus, and the myocyte progenitor (B, arrow) exhibits in its nucleus GATA-4 (A, red) and MEF2 (B, white). (C and D; the same field)
A cardiac progenitor (C, arrowhead) shows MDR1 on the surface membrane (purple) and GATA-4 (C, red) in the nucleus, and a myocyte progenitor (D, arrow) exhibits
in itsnucleusGATA-4(C, red)andMEF2(D,white). (E,F,andG)Myocyteprecursors (arrows)showonthesurfacemembranec-kit (E,green),MDR1(F,purple),orSca-1-like
(G, yellow). A thin cytoplasmic layer is positive for cardiac myosin (E–G, red) and nuclei express MEF2 (E–G, white). (Bars 10 m.)
Fig. 3. Telomerase and telomeric length. (A–D) c-kit-positive cells (green, arrows) expressing telomerase (A and C, white) in nuclei. Nuclei are also positive for
MCM5 (B and D, red). The c-kit-positive cell (C and D) has a thin myocyte cytoplasmic layer (cardiac myosin, red; arrowheads). (E) Number of primitive, early
committed cells and small amplifying myocytes expressing telomerase and MCM5. Results are mean SD. *, P 0.001 between hypertrophied (aortic stenosis,
AS) and control (C) hearts. (F) Telomerase activity in control (Con) and hypertrophied (AS) hearts; products of telomerase activity start at 50 bp and display 6-bp
periodicity. Lysates treated with RNase () were used as negative control and HeLa cells as positive control. (G) Telomeric restriction fragment lengths in control
(Con) and hypertrophied (AS) hearts; immortal cell lines of known mean telomeric length, 10.2 and 7.0 kbp, were used as baseline.
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expansion starting from a stem or amplifying cell that through a
process of cell division generated a large progeny that differen-
tiated asynchronously (Fig. 4 D and E; Fig. 15 A–H, which is
published as supporting information on the PNAS web site).
These clusters leave little doubt about the existence of stem cells
in the heart that are stimulated to amplify and commit to the
myogenic pathway in response to the increased work load
produced by aortic stenosis (Fig. 15 I–J).
Fig. 4. Intense growth in the hypertrophied heart. (A) Group of 12 c-kit-positive cells (green) surrounded by myocytes (red). Several nuclei express GATA-4 (yellow).
One cell has a thin layer of myocyte cytoplasm (myosin, red, asterisk). (B and C) A second group of nine small cells with a ring of myocyte cytoplasm (myosin, red). Three
of these cells exhibit c-kit (green; arrows) and seven (arrowheads) express both telomerase (B, white) and MCM5 (C, purple). (D) Low-power field of a cluster (rectangle)
ofsmallpoorlydifferentiatedmyocyteswithinthehypertrophiedmyocardium(HM).Myocytesare labeledbycardiacmyosin(red)andnucleibypropidiumiodide(blue).
The area in the rectangle is illustrated at higher magnification in E, in which Ki67 (yellow) labels a large number of myocyte nuclei (arrows). The two small rectangles
delimit areas shown at higher magnification in F–I. A mitotic nucleus with metaphase chromosomes (F and G; arrows) is positive for Ki67 (G, yellow) and the boundary
of the cell is defined by laminin (G, green). Another mitotic nucleus (H; arrow) is labeled by Ki67 (I, yellow; arrow). c-kit-positive cells (I, green; arrowheads) are near
the mitotic myocyte. One shows Ki67 (I, yellow; asterisk). (Bars 10 m in A–C and F–I; bars 50 m in D and E).











Amplifying and Terminally Differentiated Myocytes. Ki67, MCM5,
Cdc6, and cyclin B1 are nuclear proteins involved in the cell cycle.
Conversely, p16 induces growth arrest and cellular senescence.
These markers were measured together with myocyte diameter to
identify replicating and nonreplicating cells and their size. Ki67 and
MCM5 were introduced above. Cdc6 establishes the prereplication
complex by recruiting MCM proteins at the site of initiation of
DNA synthesis (22). Cyclin B1 accumulates in the nucleus just
before mitosis, corresponding to the onset of karyokinesis (23). p16
maintains the retinoblastoma protein Rb in its hypophosphorylated
form (24), blocking the cell cycle (Fig. 16, which is published as
supporting information on the PNAS web site).
Aortic stenosis led to 150- to 180-fold increase in the number of
Cdc6-, Ki67-, and MCM5-positive myocyte nuclei (Fig. 5; P 
0.001). Cyclin B1 was detected in 28  15106 and in 4,300 
1,500106 myocyte nuclei of control and hypertrophied hearts,
respectively. The transverse area of cycling myocytes was 60% and
80% smaller than noncycling p16-negative and p16-positive cells
(Fig. 5). Thus, small amplifying myocytes regenerate and bigger
cells may enlarge or do not respond to growth stimuli.
Myocytes in mitosis, including karyokinesis, or nuclear division,
and cytokinesis, or cell division, were identified in the hypertro-
phied hearts (Fig. 6). Mitotic myocytes increased 140-fold with
aortic stenosis, from 15  5106 in control to 2,100  740106 in
hypertrophied hearts (P 0.001). Thus, 2 of every 1,000 myocytes
were in mitosis. The ratio of myocytes traversing the cell cycle to
those in mitosis allowed us to estimate the duration of the cell cycle.
On the assumption that mitosis lasts 30 min, this parameter was
nearly 25 h when Ki67 was considered or 40 h when MCM5 was
used (1). Importantly, the number of cycling myocytes (Ki67,
MCM5, Cdc6, cyclin B1, mitotic index) was inversely correlated
with the duration of the disease from 1 year or longer (P 
0.002–0.0004).
Discussion
The most significant result of this study is that the heart possesses
primitive cells, which express surface antigens commonly detected
Fig. 5. Number and size of cycling and noncycling myocytes. Results are mean
SD. *, P0.001 between hypertrophied (AS) and control (C) hearts; †, P0.001
between cycling and noncycling p16-negative (p16-neg) and p16-positive (p16-
pos)myocytes;‡,P0.001betweennoncyclingp-16-negandnoncyclingp16-pos
myocytes.
Fig. 6. Mitosis, karyokinesis, and cytokinesis in myocytes. A, D, G, J, and M illustrate chromosomes [propidium iodide (PI), blue]. B, E, H, K, and N show Ki67
in chromosomes (yellow). C, F, I, L, and O depict the combination of cardiac myosin (red) in myocytes with PI and Ki67 staining of mitotic nuclei (bright yellow).
Arrows point to cytokinesis. (Bars  10 m.)
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on hemopoietic stem cells (5). No other markers of cardiac,
hemopoietic, skeletal muscle, and neural cell commitment have
been found. Cardiac progenitors, myocyte progenitors, and pre-
cursors positive for c-kit, MDR1, and Sca-1-reactive protein were
detected, demonstrating a link between putative cardiac stem cells
and myocyte differentiation. This lineage commitment ultimately
gave rise to small developing myocytes that further evolved into the
adult phenotype. The growth and differentiation of cardiac stem
cells in mature myocytes was markedly enhanced in the hypertro-
phied myocardium of patients with chronic aortic stenosis. In the
pressure-overloaded heart, the number of primitive and early
committed cells was only a fraction of that represented by dividing
telomerase-competent amplifying myocytes. This pattern of growth
is consistent with the activation of a restricted number of stem
cells, which have the ability to generate a large number of highly
proliferating parenchymal cells (5). The modest impairment of
ventricular function before correction of the valvular disease
suggests that the process of cell regeneration led to functionally
competent myocytes that contributed to limit the alterations
in hemodynamics. Patients with aortic stenosis have good ventric-
ular function for many years before decompensation becomes
apparent (9).
Although mechanical factors may play a role in the growth
response of the stressed heart, the local activation of genes pro-
moting cell replication and the down-regulation of genes interfering
with cell cycle entry and progression may be importantly implicated
in the growth of primitive and committed cells. For example,
inhibition of angiotensin-converting enzyme interferes with Ac-
Ser-Asp-Lys-Pro function, attenuating stem cell growth (25). This
is an interesting possibility that requires further investigation.
The recognition that the heart may belong to organs with
self-renewing property suggests that the theme of the controversy
on myocyte regeneration must be reexamined. We have proposed
that a subpopulation of myocytes in the adult heart is capable of
reentering the cell cycle and undergoing cytokinesis despite their
developed state (26). This notion was opposed by negative results
obtained after the in vivo injection of proteins interfering with p53
or other cell cycle inhibitors (27). Myocyte division was not detected
and the attempts of the cells to replicate resulted in apoptotic cell
death (27). Either position had valid points but could not provide
a logical understanding of myocyte growth or its developmental
block. These opposing views have exacerbated the debate among
laboratories, leading to two distinct paradigms of cardiac hypertro-
phy. In one, both myocyte hypertrophy and proliferation were
considered to be involved in the response of the stressed heart
whereas, in the other, only cellular hypertrophy was claimed to
contribute to cardiac enlargement (28). At present, the discrepancy
no longer exists. Dividing myocytes are amplifying cells that can
experience a finite number of divisions before reaching terminal
differentiation and growth arrest. Similarly, forced recall of differ-
entiated myocytes into the cell cycle fails to trigger DNA synthesis
and activates the endogenous cell death program.
The high degree of myocyte replication that was found here was
unexpected and surprising. For this reason, the unusual level of
myocyte regeneration was proven with several markers of the cell
cycle, Cdc6, Ki67, and MCM5 (18–20, 22) that provided compa-
rable data. Similarly, cyclin B1 labeling (23) of myocyte nuclei and
the mitotic index were consistent. However, the number of mitotic
myocytes was 4-fold and 15-fold greater than that previously
reported with acute and chronic cardiac failure (1, 3). Difficult is the
identification of the variables responsible for the difference in
myocyte division between heart failure of ischemic and nonisch-
emic origin (1, 3), and moderate ventricular dysfunction and aortic
stenosis. One critical factor could be the degree and duration of the
overload. Multiplication and differentiation of primitive and com-
mitted cells may be limited, and large stresses, acute or chronic, may
produce a progressive decline of myocardial growth. This may not
be the case with aortic stenosis and modest ventricular dysfunction.
However, telomeric shortening occurred in the presence of en-
hanced telomerase activity. The ribonucleoprotein attenuated the
process but could not prevent telomere attrition. A similar condi-
tion develops in the bone marrow with rapid cellular growth (29).
Intense cell division after bone marrow transplantation is charac-
terized by elevated telomerase activity and telomere erosion (29).
Ultimately, telomerase cannot prevent loss of DNA and growth
arrest in both systems (10).
The magnitude of stem cell-dependent myocyte regeneration
with aortic stenosis, 15%, is similar to that observed in cardiac
chimerism after transplantation of female hearts into male recip-
ients (7). Cardiac chimerism offered the unique opportunity to
recognize the formation of myocytes and vascular structures from
primitive cells resident in the heart or homed to the heart from the
circulation. The detection of the Y chromosome allowed us to
document that myocyte replication accounted for nearly 18% of the
entire cell population. This work has generated enthusiasm and
opposition in the scientific community. A series of quickly published
reports and an editorial (30) have challenged myocyte proliferation
once more. However, these studies used methodologies inadequate
for magnitude of tissue sampling and level of microscopic resolution
(31). The findings with aortic stenosis strengthen the data on
cardiac chimerism, and we hope that they will stimulate more
interest in the area of myocardial regeneration.
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